Skip to main content
Clinical Trials/NCT05278299
NCT05278299UnknownNot Applicable

Asia Glaucoma Registry

The University of Hong Kong1 site in 1 country20 target enrollmentStarted: October 1, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
20
Locations
1
Primary Endpoint
The proportion of fast progressors among patients with POAG or PACG and the risk factors for fast progression

Study Overview

Brief Summary

Glaucoma remains a leading cause for irreversible visual impairment and blindness worldwide and it disproportionately affects people residing in Asia, there is a need to ensure optimal management of the disease in patients with glaucoma. The ability to estimate the rates of structural and functional loss in patients with glaucoma will enable clinicians to identify those with rapidly deteriorating conditions or those at-risk, and to therefore provide timely treatment to these patients. Despite this, there are currently several challenges in identifying rapid-progressors in glaucoma, including lack of consensus on the definition of 'rapid' progression and what rates of change of visual field (VF) encompass clinically significant deterioration relevant to the patients. As such, the Asia Glaucoma Registry is intended to collect data to advance the understanding of glaucoma and its progression in Asia and to understand the management patterns of glaucoma in Asia. The Registry will also provide research data for future collaborative scientific research projects.

Detailed Description

Glaucoma remains a leading cause for irreversible visual impairment and blindness worldwide and it disproportionately affects people residing in Asia [Tham et al, 2014]. It is well established that the epidemiology and natural history of glaucoma in patients in the Asia region is different from its western counterparts. Compared with the other parts of the world, the prevalence of primary angle closure glaucoma (PACG) was highest in Asia [Tham et al, 2014]. The prevalence of PACG was higher in East Asia than South East Asia, while the burden of primary open angle glaucoma (POAG) was projected to be the highest in South-Central Asia by 2040 [Chan et al, 2016]; this suggests that ethnic differences within Asia may be a contributing factor to the differences in the prevalence of different types of glaucoma. Furthermore, studies have suggested the prevalence of normal pressure glaucoma is also higher in Asians than Caucasians [ Chen et al , 2020 ] Given the disproportionate burden of glaucoma in Asia, there is a need to ensure optimal management of the disease in patients with glaucoma. The ability to estimate the rates of structural and functional loss in patients with glaucoma will enable clinicians to identify those with rapidly deteriorating conditions or those at-risk, and to therefore provide timely treatment to these patients.

Despite this, there are currently several challenges in identifying rapid-progressors in glaucoma, including lack of consensus on the definition of 'rapid' progression and what rates of change of visual field (VF) encompass clinically significant deterioration relevant to the patients. As such, the Asia Glaucoma Registry is intended to collect data to advance the understanding of glaucoma and its progression in Asia and to understand the management patterns of glaucoma in Asia. The Registry will also provide research data for future collaborative scientific research projects. Glaucoma remains a leading cause for irreversible visual impairment and blindness worldwide and it disproportionately affects people residing in Asia [Tham et al, 2014]. It is well established that the epidemiology and natural history of glaucoma in patients in the Asia region is different from its western counterparts. Compared with the other parts of the world, the prevalence of primary angle closure glaucoma (PACG) was highest in Asia [Tham et al, 2014]. The prevalence of PACG was higher in East Asia than South East Asia, while the burden of primary open angle glaucoma (POAG) was projected to be the highest in South-Central Asia by 2040 [Chan et al, 2016]; this suggests that ethnic differences within Asia may be a contributing factor to the differences in the prevalence of different types of glaucoma. Furthermore, studies have suggested the prevalence of normal pressure glaucoma is also higher in Asians than Caucasians [ Chen et al , 2020 ] Given the disproportionate burden of glaucoma in Asia, there is a need to ensure optimal management of the disease in patients with glaucoma. The ability to estimate the rates of structural and functional loss in patients with glaucoma will enable clinicians to identify those with rapidly deteriorating conditions or those at-risk, and to therefore provide timely treatment to these patients.

Despite this, there are currently several challenges in identifying rapid-progressors in glaucoma, including lack of consensus on the definition of 'rapid' progression and what rates of change of visual field (VF) encompass clinically significant deterioration relevant to the patients. As such, the Asia Glaucoma Registry is intended to collect data to advance the understanding of glaucoma and its progression in Asia and to understand the management patterns of glaucoma in Asia. The Registry will also provide research data for future collaborative scientific research projects.

References:

Chan EW, et al. Glaucoma in Asia: regional prevalence variations and future projections. Br J Opthalmol 2016;100(1):78-85.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with a diagnosis of POAG or PACG
  • Age ≥18 years at diagnosis.
  • Have reliable VF tests obtained from Humphrey Field Analyzer (HFA) using the same testing strategy on average once a year over 6-7 years backward in at least one eye (the included eye must have evidence of glaucoma as defined above). A reliable VF test has fixation losses ≤20% and false positive errors ≤15%. All criteria mentioned above must be met for inclusion into the study. Both eyes will be included if both eyes meet the inclusion criteria.

Exclusion Criteria

  • Secondary causes of glaucoma (e.g. uveitic glaucoma, neovascular glaucoma, traumatic glaucoma, exfoliative glaucoma, pigmentary glaucoma, phacomorphic glaucoma, malignant glaucoma)
  • Any neurological disease that may result in VF loss (e.g. stroke)
  • History of optic neuropathy other than glaucoma (including those related to thyroid eye disease);
  • Prior retinal surgery.

Outcomes

Primary Outcomes

The proportion of fast progressors among patients with POAG or PACG and the risk factors for fast progression

Time Frame: 1 year

Secondary Outcomes

  • The severity and spectrum of glaucoma in different ethnic groups in Asia and the practice patterns of glaucoma management in Asia(1 year)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Prof Leung Kai Shun, Christopher

Head and Clinical Professor

The University of Hong Kong

Study Sites (1)

Loading locations...

Similar Trials